EMA Application withdrawn: Aripiprazole Mylan (aripiprazole) — Generics (UK) Limited

View source ↗

Summary

The EMA report indicates withdrawal of the aripiprazole generic application from Generics (UK) Limited for schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Aripiprazole (Generics) (aripiprazole)

Snippet

Status: Application withdrawn. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Generics (UK) Limited. Decision date: 22/05/2015